We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

14 hedge funds and large institutions have $2.3M invested in VistaGen Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

17% more funds holding

Funds holding: 12 → 14 (+2)

2.7% less ownership

Funds ownership: 15.96% → 13.26% (-2.7%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

91% less capital inflows, than outflows

Capital inflows: $27.8K | Capital outflows: $293K

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.A. Davidson & Co
D.A. Davidson & Co
Montana
+$14.6K
2
UBS Group
UBS Group
Switzerland
+$11.9K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$1.11K
4
Proficio Capital Partners
Proficio Capital Partners
Massachusetts
+$176

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$289K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$4.16K

VTGN Hedge Fund Activity: Q2 2017 in Review

14 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2017, worth a combined $2.3M — down 14% from $2.68M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new VTGN positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was D.A. Davidson & Co, adding an estimated $14.6K. The largest seller was Sabby Management, cutting an estimated $289K.

  • 14 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2017, up from 12 in Q1 2017.
  • Funds reported $2.3M of VistaGen Therapeutics stock for Q2 2017, down 14% quarter-over-quarter.
  • 3 funds opened new VistaGen Therapeutics positions in Q2 2017 and 1 closed out, a net change of +2 holders.
  • The largest VistaGen Therapeutics buyer in Q2 2017 was D.A. Davidson & Co, an estimated $14.6K added.
  • The largest VistaGen Therapeutics seller in Q2 2017 was Sabby Management, an estimated $289K sold.

Based on aggregated 13F filings for Q2 2017.